CN117460513A - 组合疗法 - Google Patents

组合疗法 Download PDF

Info

Publication number
CN117460513A
CN117460513A CN202280034525.XA CN202280034525A CN117460513A CN 117460513 A CN117460513 A CN 117460513A CN 202280034525 A CN202280034525 A CN 202280034525A CN 117460513 A CN117460513 A CN 117460513A
Authority
CN
China
Prior art keywords
alkyl
formula
group
ethyl
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280034525.XA
Other languages
English (en)
Chinese (zh)
Inventor
N·达斯卡拉基斯
C·D·古特克
权珉彻
L·A·费兰特
K·E·帕克曼
E·C·皮奇
U·费里帕尔
T·A·J·韦尔胡尔斯特
B·博加尔
孙宇
蔡伟
戴学东
O·A·G·凯罗勒
J·W·J·图灵
刘颖涛
刘连柱
徐彦平
付利强
厉铭
方李超
邓向君
A·T·F·吴
N·F·J·达尔维尔
V·潘德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to CN202410897512.6A priority Critical patent/CN118845787A/zh
Publication of CN117460513A publication Critical patent/CN117460513A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280034525.XA 2021-05-11 2022-05-09 组合疗法 Pending CN117460513A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410897512.6A CN118845787A (zh) 2021-05-11 2022-05-09 组合疗法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2021093036 2021-05-11
CNPCT/CN2021/093036 2021-05-11
CN2021100523 2021-06-17
CNPCT/CN2021/100523 2021-06-17
CN2022086004 2022-04-11
CNPCT/CN2022/086004 2022-04-11
PCT/CN2022/091679 WO2022237720A1 (en) 2021-05-11 2022-05-09 Combination therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410897512.6A Division CN118845787A (zh) 2021-05-11 2022-05-09 组合疗法

Publications (1)

Publication Number Publication Date
CN117460513A true CN117460513A (zh) 2024-01-26

Family

ID=81753154

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202280034525.XA Pending CN117460513A (zh) 2021-05-11 2022-05-09 组合疗法
CN202410897512.6A Pending CN118845787A (zh) 2021-05-11 2022-05-09 组合疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410897512.6A Pending CN118845787A (zh) 2021-05-11 2022-05-09 组合疗法

Country Status (16)

Country Link
EP (1) EP4337216A1 (https=)
JP (1) JP2024518497A (https=)
KR (1) KR20240006631A (https=)
CN (2) CN117460513A (https=)
AU (1) AU2022274071A1 (https=)
CA (1) CA3215313A1 (https=)
CL (2) CL2023003239A1 (https=)
CO (1) CO2023014322A2 (https=)
DO (1) DOP2023000246A (https=)
IL (1) IL308335A (https=)
MX (1) MX2023013410A (https=)
PE (1) PE20240593A1 (https=)
PH (1) PH12023552974A1 (https=)
TW (1) TW202308643A (https=)
UY (1) UY39761A (https=)
WO (1) WO2022237720A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12473295B2 (en) 2019-12-19 2025-11-18 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4626426A1 (en) * 2022-11-30 2025-10-08 JANSSEN Pharmaceutica NV Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
WO2024114666A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
EP4698182A1 (en) * 2023-04-17 2026-02-25 Janssen Pharmaceutica NV Combination of a menin-ll1 inhibitor, a dna intercalating agent and a pyrimidine analogue to treat a hematopoietic disorder
WO2025082444A2 (en) * 2023-10-20 2025-04-24 Janssen Pharmaceutica Nv (r) -n-ethyl-5-fluoro-n-isopropyl-2- ( (5- (2- (6- ( (2-methoxyethyl) (methyl) amino) -2-methylhexan-3-yl) -2, 6-diazaspiro [3.4] octan-6-yl) -1, 2, 4-triazin-6-yl) oxy) benzamide, formulations and dosage regimens thereof, for use in treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000080A1 (en) 2014-12-18 2018-07-04 Takeda Pharmaceuticals Co Solid state forms of fused heteroaromatic pyrrolidinones
AU2016378579A1 (en) * 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
WO2017214367A1 (en) * 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12473295B2 (en) 2019-12-19 2025-11-18 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives

Also Published As

Publication number Publication date
AU2022274071A1 (en) 2024-01-04
MX2023013410A (es) 2023-12-06
JP2024518497A (ja) 2024-05-01
CO2023014322A2 (es) 2023-11-20
DOP2023000246A (es) 2024-04-30
IL308335A (en) 2024-01-01
CL2024002832A1 (es) 2025-02-14
CA3215313A1 (en) 2022-11-17
PH12023552974A1 (en) 2024-03-11
CL2023003239A1 (es) 2024-06-07
PE20240593A1 (es) 2024-03-21
TW202308643A (zh) 2023-03-01
CN118845787A (zh) 2024-10-29
UY39761A (es) 2022-11-30
EP4337216A1 (en) 2024-03-20
WO2022237720A1 (en) 2022-11-17
KR20240006631A (ko) 2024-01-15

Similar Documents

Publication Publication Date Title
TWI878414B (zh) 經取代之直鏈螺環接衍生物
JP7420847B2 (ja) Ｅｈｍｔ１およびｅｈｍｔ２阻害剤としてのアミン置換アリールまたはヘテロアリール化合物
CN117460513A (zh) 组合疗法
CN118845786A (zh) 组合疗法
CN120322430A (zh) Pcsk9抑制剂及其使用方法
CN102573484A (zh) 苄基取代的三嗪衍生物及其治疗应用
CN117597348A (zh) 用于治疗诸如癌症的疾病的(r)-n-乙基-5-氟-n-异丙基-2-((5-(2-(6-((2-甲氧基乙基)(甲基)氨基)-2-甲基己-3-基)-2,6-二氮杂螺[3.4]辛-6-基)-1,2,4-三嗪-6-基)氧基)苯甲酰胺苯磺酸盐
CN120322230A (zh) 包含多发性内分泌癌蛋白-mll抑制剂和至少一种其他治疗剂的组合
WO2024114666A1 (en) Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
HK40117870A (zh) 组合疗法
HK40100348A (zh) 组合疗法
HK40118806A (zh) 组合疗法
HK40098242A (zh) 组合疗法
US20250302840A1 (en) Combination therapies
HK40113255A (zh) 取代的直链螺环衍生物
EA051809B1 (ru) Комбинированные терапии
EA051795B1 (ru) Комбинированные терапии
HK40071760A (en) Substituted straight chain spiro derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40100348

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination